Int J Sports Med 2006; 27(3): 187-192
DOI: 10.1055/s-2005-865627
Physiology & Biochemistry

© Georg Thieme Verlag KG Stuttgart · New York

Urinary and Blood Concentrations of β2-Agonists in Trained Subjects: Comparison between Routes of Use

A. Pichon1 , N. Venisse2 , E. Krupka3 , M.-C. Pérault-Pochat3 , A. Denjean1 , 4
  • 1Laboratoire des Adaptations Physiologiques aux Activités Physiques, Faculté des Sciences du Sport, UPRES EA 3813, Poitiers, France
  • 2Service de Pharmacocinétique, CHU de Poitiers, Poitiers, France
  • 3Service de Pharmacologie Clinique, Centre de Recherche Clinique du CHU de Poitiers, Poitiers Cedex, France
  • 4Service d'Explorations Fonctionnelles, Physiologie Respiratoire et de l'Exercice, Pôle Cœur-Poumons, CHU de Poitiers, Poitiers, France
Further Information

Publication History

Accepted after revision: March 7, 2005

Publication Date:
30 August 2005 (online)

Abstract

We aimed to assess the plasma and urine concentrations of β2-agonists and evaluate the difference between three routes of administration in trained adults in order to distinguish doping from prevention of exercise-induced asthma. Ten young healthy Caucasian male subjects received during a four treatment period study: 1) inhaled salbutamol (SI) 2 × 100 µg t.i.d. for 3 days, 2) inhaled formoterol (FI) 2 × 12 µg b.i.d. for 3 days, 3) a single subcutaneous injection of salbutamol (SS) 0.5 mg, and 4) salbutamol 2 × 2 mg t.i.d. orally for 3 days (SO). Blood samples were taken during the first and the third day of experimentation at baseline, 30 min, 1 h, 2 h, 4 h and 6 h after administration; additional blood samples were drawn at 15 min for SI, SS and FI and at 12 h for FI. Urinary samples were collected at baseline, 2 h, 4 h, 6 h and 12 h after administration. Urinary concentrations were 20 to almost 50 times higher after SO than after SI. Mean urinary concentration after SO increased to above 800 ng · mL-1 within the two hours and above 1000 ng · mL-1 at 6 to 12 hours post-drug administration. Urinary concentrations after SS were maximal during the first 2 hours (mean: 340 ± 172 ng · mL-1). Plasma concentrations were very low, whatever the routes of administration. Results showed that we could eliminate the use of SI (authorized) and SS administration when individual urinary concentrations are higher than 230 ng · mL-1 and 615 ng · mL-1, respectively. Therefore, at rest, the cut-off value used to discriminate therapeutic from doping salbutamol intake could be fixed at 250 ng · mL-1 instead of the 1000 ng · mL-1 still authorized by international committees.

References

  • 1 Berges R, Segura J, Ventura R, Fitch K D, Morton A R, Farre M, Mas M, de la Torre X. Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment.  Clin Chem. 2000;  46 1365-1375
  • 2 Berges R, Segura J, de la Torre X, Ventura R. Analytical methodology for enantiomers of salbutamol in human urine for application in doping control.  J Chromatogr B Biomed Sci Appl. 1999;  723 173-184
  • 3 Boulton D W, Fawcett J P. Determination of salbutamol enantiomers in human plasma and urine by chiral high-performance liquid chromatography.  J Chromatogr B Biomed Appl. 1995;  672 103-109
  • 4 Carlsen K H, Hem E, Stensrud T, Held T, Herland K, Mowinckel P. Can asthma treatment in sports be doping? The effect of the rapid onset, long-acting inhaled beta2-agonist formoterol upon endurance performance in healthy well-trained athletes.  Respir Med. 2001;  95 571-576
  • 5 Collomp K, Candau R, Collomp R, Carra J, Lasne F, Prefaut C, De Ceaurriz J. Effects of acute ingestion of salbutamol during submaximal exercise.  Int J Sports Med. 2000;  21 480-484
  • 6 Collomp K, Candau R, Lasne F, Labsy Z, Prefaut C, De Ceaurriz J. Effects of short-term oral salbutamol administration on exercise endurance and metabolism.  J Appl Physiol. 2000;  89 430-436
  • 7 Fleck S J, Lucia A, Stroms W W, Wallach J M, Vint P F, Zimmerman S O. Effects of acute inhalation of albuterol on submaximal and maximal V·O2 and blood lactate.  Int J Sports Med. 1993;  14 239-243
  • 8 Freeman W, Packe G E, Cayton R M. Effect of nebulised salbutamol on maximal exercise performance in men with mild asthma.  Thorax. 1989;  44 942-947
  • 9 Goubault C, Perault M C, Leleu E, Bouquet S, Legros P, Vandel B, Denjean A. Effects of inhaled salbutamol in exercising non-asthmatic athletes.  Thorax. 2001;  56 675-679
  • 10 Hankinson J L, Bang K M. Acceptability and reproducibility criteria of the American Thoracic Society as observed in a sample of the general population.  Am Rev Respir Dis. 1991;  143 516-521
  • 11 Meeuwisse W H, McKenzie D, Hopkins S R, Road J D. The effect of salbutamol on performance in elite non-asthmatic athletes.  Med Sci Sports Exerc. 1992;  24 1161-1166
  • 12 Morton A R, Papalia S M, Fitch K D. Is salbutmol ergogenic? The effect of salbutamol on physical performance in high-performance non-asthmatic athletes.  Clin J Sports Med. 1992;  2 93-97
  • 13 Roig M, Berges R, Ventura R, Fitch K D, Morton A R, Segura J. Quantification of terbutaline in urine by enzyme-linked immunosorbent assay and capillary electrophoresis after oral and inhaled administrations.  J Chromatogr B Analyt Technol Biomed Life Sci. 2002;  768 315-324
  • 14 Schmidt A, Diamant B, Bundgaard A, Madsen P L. Ergogenic effect of inhaled β2-agonists in asthmatics.  Int J Sports Med. 1988;  9 338-340
  • 15 Shapiro G S, Yegen U, Xiang J, Kottakis J, Della Cioppa G. A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol.  Clin Ther. 2002;  24 2077-2087
  • 16 Signorile J F, Kaplan T A, Applegate B, Perry A C. Effects of acute inhalation of the bronchodilatator, albuterol, on power output.  Med Sci Sports Exerc. 1992;  24 638-642
  • 17 van Noord J A, Smeets J J, Raaijmakers J A, Bommer A M, Maesen F P. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action.  Eur Respir J. 1996;  9 1684-1688
  • 18 Ventura R, Segura J, Fitch K D, Morton A R, Berges R, Jimenez C, Berruezo S. Distinction of inhaled and oral salbutamol by urine analysis using conventional screening procedures for doping control.  Ther Drug Monit. 2000;  22 277-282
  • 19 Voy R O. The U. S. Olympic Committee experience with exercise-induced bronchospasm.  Med Sci Exerc. 1986;  18 328-330
  • 20 Weiler J M, Layton T, Hunt M. Asthma in United States Olympic athletes who participated in the 1996 Summer Games.  J Allergy Clin Immunol. 1998;  102 722-726
  • 21 World Anti-Doping Agency .The 2004 Prohibited List. Montreal, Quebec, Canada; World Anti-Doping Code 2004: 5

Aurélien Pichon

Laboratoire «Réponses cellulaires et fonctionnelles à l'hypoxie»
UFR «Santé, Médecine, Biologie Humaine»

74 rue Marcel Cachin

93017 Bobigny

France

Phone: + 33(0)148387632

Phone: + 33(0)682951970

Fax: + 33 (0) 1 48 38 77 33

Fax: + 33 (0) 1 48 38 77 77

Email: aurelien.pichon@orange.fr

    >